Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px download
Document › Details

Kiadis Pharma N.V.. (8/17/17). "Press Release: Kiadis Pharma Obtains up to €15 Million Debt Financing from Kreos Capital". Amsterdam-Duivendrecht.

Organisations Organisation Kiadis Pharma N.V. (Euronext: KDS)
  Group Kiadis (Group)
  Organisation 2 Kreos V Fund
  Group Kreos Capital (Group)
Products Product ATIR101™ (Kiadis)
  Product 2 finance
Index term Index term Kiadis–Kreos Capital: credit, 201708– debt financing up to €15m in 2 tranches 10% annual interest + end of loan 5% of drawn amount + 254k warrants
Persons Person Lahr, Arthur (Kiadis 201704– CEO before Crucell 200701 Chief Strategy Officer + EP Sales + BusDev)
  Person 2 PetitBon, Maurizio (Kreos Capital 201401 General Partner joined 1998 bfore PMA Europe + SRI Intl)
     


Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that it has obtained a debt facility of up to €15 million from Kreos Capital.

The loan consists of two tranches, with the first tranche of €10 million immediately drawn down and a second tranche of €5 million upon the company raising €20 million in additional funds. Kiadis Pharma will use the loan to advance the development of the Company’s ATIR products, for general corporate purposes and to repay the remaining €5.3 million of existing Dutch Government Loans.

Arthur Lahr, CEO of Kiadis Pharma, commented: “We are pleased with this non-dilutive debt funding from Kreos Capital, Europe’s largest provider of debt-financing solutions to high-growth companies. The loan allows us to refinance an existing loan with improved terms and extends our cash runway, as we progress towards potentially obtaining marketing approval for ATIR101™ in the European Union in the second half of 2018.”

Maurizio PetitBon, General Partner of Kreos Capital, commented: “We are pleased to be supporting Kiadis Pharma, a company that is advancing the field of allogeneic hematopoietic stem cell transplantations and is improving the outcomes of patients suffering from blood cancers and inherited blood disorders. The flexible funding provided by Kreos will provide a strong foundation for Kiadis to advance the development of ATIR101™.”


About the loan agreement

Draw down
Tranche A: €10 million upon closing
Tranche B: €5 million conditional upon the Company raising at least €20 million of additional funds before 1 July 2018

Term
Tranche A: 45 months
Tranche B: 48 months

Repayment
Tranche A: Interest only for the first 9 months, with the remaining 36 months amortizing in equal monthly instalments comprising principal and interest
Tranche B: Interest only for the first 12 months, with the remaining 36 months amortizing in equal monthly instalments comprising principal and interest

Interest
10% annual fixed interest rate
End of loan payment
5% of the amount drawn down

Structure
Security over assets including IP; no financial covenants

Warrants
Up to 253,617 warrants, of which 211,348 issued at closing, entitling Kreos Capital to subscribe for up to 253,617 new Company shares at a warrant exercise price of €6.36 (the exercise price being subject to adjustment in case of certain corporate and dilutive events)
 

About ATIR101™

For patients suffering from blood cancers and inherited blood disorders, an allogeneic hematopoietic stem cell transplantation (HSCT) can offer a cure, yet it has considerable risks. During an HSCT treatment, the patient’s diseased blood and immune system are destroyed and subsequently replaced by a healthy system from a donor. The key challenge with HSCT is that mature lymphocytes from the donor are required to provide immediate protection against infections and relapse, but may attack patient tissue, causing life threatening Graft-versus-Host-Disease (GVHD).

ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) provides for a single dose donor lymphocyte infusion, with functional, mature immune cells from a haploidentical family member, given as an adjunctive to a haploidentical HSCT. The lymphocytes in ATIR101™ are very potent in fighting infections and remaining tumor cells, yet do so with minimal risk of causing severe GVHD. To provide protection to patients without attacking patient tissue, ATIR101™ is manufactured by depleting patient specific alloreactive lymphocytes ex vivo from donor material. ATIR101™ offers a strong improvement in relapse rates and GVHD over literature for other HSCT protocols, such as the Post Transplant Cyclophosphamide (PTCy) or ‘Baltimore’ protocol.

About Kiadis Pharma

Kiadis Pharma is focused on cell-based immunotherapy products, as an adjunctive to a haploidentical hematopoietic stem cell transplantation (HSCT), for the treatment of blood cancers and inherited blood disorders. The Company’s product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.

Based on the positive results from the single dose Phase II trial with lead product ATIR101™ in patients with blood cancer, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101™ across the European Union as an adjunctive treatment in HSCT for malignant disease. In addition, Kiadis Pharma has received regulatory approval in various countries to start dosing patients in a Phase III trial with ATIR101™ that will be performed across Europe and North America. ATIR101™ has been granted Orphan Drug Designations both in the US and Europe.

The Company’s second product candidate, ATIR201™, will address beta thalassemia, an inherited blood disorder.

Kiadis Pharma was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the EMA.

The Company’s shares are listed on Euronext Amsterdam and Euronext Brussels. For more information visit www.kiadis.com


About Kreos

Kreos Capital has been prominent for 19 years as the leading provider of growth debt financing in Europe and Israel to high-growth companies with revenues up to USD 200 million. As the pioneer growth debt provider across Europe and Israel, Kreos has completed over 450 transactions and committed USD 1.9 billion in 15 different countries. Kreos is dedicated to supporting management teams and their equity investors with flexible loan structures for all stages of a growth company’s development, and to addressing the needs for growth capital, working capital, acquisition financings, lower mid-market buy-outs, roll-up strategies, bank re-financings as well as pre- and post-IPO financings. Kreos’s most recent fund, Kreos V, was launched in January 2016 with USD 440 million committed from top-tier institutional investors for investment in our portfolio companies.


For more information, please contact:

For more information, please contact:
Arthur Lahr, CEO
Kiadis Pharma
Tel. +31 20 314 02 50
communication@Kiadis.com

International Media and Investor Contact:
Mary-Jane Elliott, Lindsey Neville, Hendrik Thys
Consilium Strategic Communications
Tel: +44 (0) 203 709 5708
Kiadis@consilium-comms.com


Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

   
Record changed: 2017-08-24

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 600x60px

More documents for Kiadis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px